# Clinical Pathophysiology and Multi-Tiered Risk Assessment of Low-Dose Aspirin in Chronic Liver Disease

The clinical safety and therapeutic efficacy of low-dose aspirin () in patients with a history of liver problems have undergone a profound paradigm shift over the last decade. Historically, hepatic impairment, particularly in the stage of cirrhosis, was viewed as a primary contraindication for any nonsteroidal anti-inflammatory drug (NSAID) due to the heightened risk of gastrointestinal hemorrhage and acute renal failure.1 However, contemporary data from high-volume retrospective cohorts and preliminary randomized controlled trials suggest a far more nuanced landscape. In the earlier stages of chronic liver disease (CLD), specifically in metabolic dysfunction-associated steatotic liver disease (MASLD) and chronic viral hepatitis, low-dose aspirin may function as a potent chemopreventive and anti-fibrotic agent.3 Conversely, as liver disease progresses toward decompensation, the drug’s impact on renal prostaglandins and portal hemodynamics introduces risks that often eclipse its preventive benefits.1 This report synthesizes the biochemical mechanisms, longitudinal clinical outcomes, and society-level guidelines to delineate the safety boundaries of aspirin use across the spectrum of liver pathology.

## Biochemical Mechanisms and Hepatic Metabolic Alterations

The pharmacokinetics of aspirin are fundamentally altered by the degree of hepatic impairment, influencing both its safety profile and its systemic availability. Under normal physiological conditions, aspirin is rapidly hydrolyzed to salicylic acid in the gastrointestinal tract, blood, and liver.8 This metabolite is subsequently detoxified in the liver via two primary pathways: glucuronidation and glycine conjugation.8 Glycine conjugation is a multi-step mitochondrial process where salicylic acid is activated to salicyl-CoA by acyl-CoA synthetase medium-chain family member 2B (), followed by conversion to salicyluric acid by glycine N-acyltransferase ().8

In patients with advanced liver disease or hepatocellular carcinoma (HCC), these mitochondrial pathways are often significantly downregulated.8 Specifically, the expression of  and  is frequently impaired in cirrhotic and malignant hepatocytes, leading to a reduced capacity for salicylate detoxification.8 This metabolic bottleneck can result in the accumulation of salicylate even at daily low doses, potentially predisposing the patient to systemic toxicity or localized hepatic stress. Furthermore, the hypoalbuminemia common in cirrhosis increases the free, pharmacologically active fraction of salicylic acid, as the drug is normally highly protein-bound.9 This increased free fraction may exacerbate the inhibition of renal prostaglandins, a critical safety concern in advanced liver disease.2

### Comparative Pharmacokinetics and Antiplatelet Mechanisms

| **Pharmacological Parameter** | **Aspirin (Acetylsalicylic Acid)** | **Clopidogrel (Thrombocyte P2Y12 Inhibitor)** |
| --- | --- | --- |
| **Active Metabolite Formation** | Rapid hydrolysis to salicylic acid 9 | -dependent activation of prodrug 10 |
| **Primary Target Enzyme** | Irreversible  and  8 | ADP receptor 11 |
| **Impact on Renal Prostaglandins** | Significant inhibition of  and  2 | Minimal to no impact on renal prostaglandins 10 |
| **Liver Impairment Dosing** | Avoid in severe failure (Child-Pugh C) 2 | No dose adjustment usually required 10 |
| **Detoxification Pathway** | Mitochondrial Glycine Conjugation () 8 | Multiple  pathways (, , ) 10 |

The inhibition of cyclooxygenase-1 () by aspirin in platelets leads to a permanent reduction in thromboxane  () production for the lifespan of the platelet, approximately 7 to 10 days.8 While this is the desired effect for cardiovascular prophylaxis, it presents a challenge in liver disease patients who may already harbor a fragile hemostatic balance due to thrombocytopenia from hypersplenism and reduced hepatic synthesis of coagulation factors.2

## Aspirin in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

MASLD, formerly known as non-alcoholic fatty liver disease (NAFLD), is currently the most prevalent chronic liver condition globally, characterized by intrahepatic lipid accumulation and varying degrees of inflammation and fibrosis.13 Emerging evidence suggests that low-dose aspirin may modulate the metabolic and inflammatory environment of the liver, potentially slowing disease progression.3

### Clinical Trial Evidence for Steatosis Reduction

A landmark 6-month, randomized, double-blind, placebo-controlled phase 2 trial evaluated the effect of 81 mg daily aspirin on 80 adults with established MASLD without cirrhosis.3 The primary endpoint was the mean change in intrahepatic lipid content (IHL) measured by proton magnetic resonance spectroscopy (). The findings indicated a significant reduction in liver fat and markers of hepatic injury.

| **Endpoint (at 6 Months)** | **Aspirin Group (n=40)** | **Placebo Group (n=40)** | **Mean Difference (95% CI)** | **P-Value** |
| --- | --- | --- | --- | --- |
| **Absolute Change in IHL (%)** | -7.3% | +3.0% | -10.3% (-17.9 to -2.8) | 0.009 3 |
| **Relative IHL Reduction (%)** | -17.3% | +30.3% (increase) | -47.6% | 0.007 3 |
| **cT1 Score (Fibro-inflammation)** | -18.8 | +29.2 | -48.0 | 0.011 3 |
| **ALT Reduction (U/L)** | Significant improvement | Minimal change | N/A | Observed 3 |

The reduction in the corrected T1 (cT1) score is particularly noteworthy, as this imaging-based biomarker correlates with both hepatic inflammation and early-stage fibrosis.3 The biochemical mechanism behind this fat reduction is hypothesized to involve aspirin’s ability to suppress pro-inflammatory lipid mediators and potentially modulate acetyl-CoA metabolism within the mitochondria, although definitive causal pathways in humans remain under investigation.8 Interestingly, this benefit was observed without significant changes in body weight, suggesting a direct hepatic metabolic effect rather than a secondary result of weight loss.3

### Longitudinal Trends in MASLD Populations

While short-term trials demonstrate improvements in surrogate markers, long-term cohort studies have yielded more complex results. A large-scale analysis of MASLD patients over a three-year period did not find a statistically significant reduction in overall mortality or HCC incidence among aspirin users compared to non-users.5 However, a discernible trend toward lower liver-related mortality and HCC was noted, particularly in patients who maintained therapy for longer durations.5

Data from the UK Biobank and the Korean National Health Insurance Service (NHIS) further reinforce the potential chemopreventive role of aspirin in MASLD.6 In the NHIS cohort, aspirin use was associated with an adjusted subdistribution hazard ratio (ASHR) of 0.86 for HCC development in MASLD patients.6 This finding was complemented by Mendelian randomization studies, which utilized genomic risk scores (GRS) for salicylic acid as a proxy for long-term aspirin exposure, showing a significant protective effect against HCC (ASHR 0.47 in the MASLD group).6 These insights suggest that while aspirin might not rapidly reverse established advanced fibrosis, its long-term use may significantly alter the oncogenic trajectory of the disease.

## Chemoprevention of Hepatocellular Carcinoma in Viral Hepatitis

Chronic viral hepatitis (HBV and HCV) remains a primary driver of liver-related mortality and malignant transformation. Extensive epidemiological data, particularly from Sweden and Taiwan, have demonstrated a robust inverse relationship between low-dose aspirin use and the incidence of HCC in these populations.20

### Duration and Dose-Dependent Risk Reduction

A nationwide Swedish study encompassing over 50,000 adults with chronic HBV or HCV found that long-term low-dose aspirin (less than 163 mg/day) was associated with a significant reduction in HCC incidence and liver-related deaths.22 The magnitude of this benefit was directly correlated with the duration of therapy.

| **Duration of Aspirin Use** | **Hazard Ratio (HR) for HCC** | **95% Confidence Interval** |
| --- | --- | --- |
| **3 months to <1 year** | 1.00 (Reference) | N/A |
| **1 to <3 years** | 0.90 | (0.76–1.06) |
| **3 to <5 years** | 0.66 | (0.56–0.78) |
| **5 or more years** | 0.57 | (0.42–0.70) |

Importantly, this study observed that the 10-year risk of gastrointestinal (GI) bleeding was 7.8% for aspirin users compared to 6.9% for non-users—a difference that did not reach statistical significance.22 This suggests that in patients with chronic hepatitis who have not yet reached the stage of decompensated cirrhosis, the benefit-to-risk ratio for chemoprevention is highly favorable. The protective effect is believed to stem from aspirin’s inhibition of platelet-derived growth factor (PDGF) signaling and its attenuation of the chronic inflammatory milieu that drives hepatocarcinogenesis.24

### Insights from the HBV-Related Cirrhosis Cohorts

In patients specifically diagnosed with HBV-related cirrhosis, the data are more nuanced. A 3-year landmark analysis from South Korea found that aspirin users had a 10-year cumulative incidence of HCC of 41.8%, compared to 46.5% for non-users (aHR 0.84, p=0.013).20 However, unlike the unselected viral hepatitis population, these cirrhotic patients did experience a significantly higher incidence of GI bleeding (29.5% vs. 24.0%, aHR 1.20, p=0.029).20 This highlight that while the anti-cancer properties of aspirin persist in the cirrhotic liver, the pharmacological safety threshold is concurrently lowered by the physiological consequences of portal hypertension and coagulopathy.2

## Safety Hazards and Pathophysiology in Decompensated Cirrhosis

The transition from compensated to decompensated cirrhosis marks a fundamental shift in the safety of aspirin therapy. In patients with advanced liver disease, particularly those presenting with ascites, the administration of aspirin is associated with two primary catastrophic risks: variceal hemorrhage and acute renal failure.1

### The Renal Prostaglandin Crisis and Hepatorenal Syndrome

In the advanced stages of cirrhosis, systemic arterial vasodilation (mediated by nitric oxide and other vasodilators) leads to a reduction in effective arterial blood volume.30 To counteract this, the body activates the renin-angiotensin-aldosterone system (RAAS) and the sympathetic nervous system, resulting in profound renal vasoconstriction.31 In this state, renal perfusion and glomerular filtration are heavily dependent on the vasodilatory effects of intrarenal prostaglandins, specifically  and .2

Aspirin, even at low doses, inhibits the cyclooxygenase enzymes responsible for prostaglandin synthesis.2 In a healthy individual, this inhibition is well-tolerated because renal blood flow is not maximally dependent on prostaglandins. In a patient with decompensated cirrhosis and ascites, however, aspirin-induced prostaglandin inhibition can lead to:

1. **Volume-Dependent Renal Failure**: A rapid decline in GFR as the renal vascular bed loses its compensatory vasodilatory support.2
2. **Precipitation of Hepatorenal Syndrome (HRS)**: Aspirin is recognized as a nephrotoxic trigger that can accelerate the transition to functional renal failure, characterized by a median survival of only weeks in its acute form (HRS-AKI) without intervention.31
3. **Diuretic Blunting**: Prostaglandins are required for the optimal efficacy of loop diuretics (furosemide) and aldosterone antagonists (spironolactone).2 Aspirin use can thus lead to refractory ascites and worsening edema.2

### Gastrointestinal and Variceal Hemorrhage Risks

Portal hypertension in cirrhosis leads to the development of portosystemic shunts, most notably esophageal and gastric varices.1 The thin-walled vessels of these varices are prone to rupture, a condition that is exacerbated by aspirin’s antiplatelet effects and its potential to cause direct gastric mucosal irritation.2

A critical case-control study found that cirrhotic patients who presented with portal hypertension-related bleeding were significantly more likely to have used aspirin in the preceding week (OR 4.9, p=0.007).2 This risk is further compounded by the thrombocytopenia common in these patients; while aspirin therapy is generally considered safe with platelet counts above 50,000/µL, many decompensated patients fall well below this threshold.2

## Staging-Based Risk Stratification and Guidelines

Clinical guidelines from the AASLD and EASL provide a structured framework for evaluating aspirin safety based on disease severity, primarily utilizing the Child-Pugh and MELD (Model for End-Stage Liver Disease) classification systems.1

### Child-Pugh Staging and Clinical Recommendations

| **Child-Pugh Score** | **Clinical Classification** | **Aspirin Use Recommendation** |
| --- | --- | --- |
| **5–6 (Class A)** | Compensated Cirrhosis | Use with extreme caution for short durations if absolutely necessary (e.g., secondary CVD prevention).2 |
| **7–9 (Class B)** | Moderate Decompensation | Generally contraindicated; high risk of bleeding and renal impairment.2 |
| **10–15 (Class C)** | Severe Decompensation | Absolutely contraindicated; extreme risk of AKI, HRS, and lethal hemorrhage.2 |

For patients with Child-Pugh A cirrhosis, low-dose aspirin may be considered if the cardiovascular or chemopreventive benefit is substantial.2 For example, the largest retrospective cirrhotic cohort study (over 66,000 patients in Taiwan) found that daily low-dose aspirin (75–100 mg) was associated with a lower risk of HCC (HR 0.37 for use  months) and lower overall mortality without a significant increase in GI bleeding.24 However, this study may have benefited from "immortal time bias" and the fact that patients stable enough to take aspirin for three consecutive years are inherently healthier than those who cannot.5

### MELD Score and Renal Monitoring

The MELD score is a critical predictor of short-term mortality and is used for liver transplant allocation.38 Because the score heavily weights serum creatinine, it serves as a dynamic indicator of renal stability. In patients with an escalating MELD score or those with a baseline MELD , the use of aspirin is hazardous due to the imminent risk of HRS.38

| **MELD Score Range** | **3-Month Mortality Risk** | **Clinical Context for Aspirin** |
| --- | --- | --- |
| **< 10** | ~1.9% | Lowest risk; aspirin used if strong cardiac/cancer indication exists.38 |
| **10–19** | ~6% | Increased risk; close monitoring of renal function required.40 |
| **20–29** | ~19.6% | High risk; aspirin generally avoided unless life-saving (e.g., recent PCI).38 |
| **30+** | >50% | Aspirin essentially contraindicated due to severe hepatic and renal failure.38 |

## Direct Hepatotoxicity and Reye's Syndrome

Aside from its effects on hemodynamics and hemostasis, aspirin can exert direct toxic effects on the liver. This is typically categorized into predictable, dose-related enzyme elevations and the idiosyncratic, pediatric-specific Reye's syndrome.35

### Salicylate-Induced Enzyme Elevations

Aspirin is considered an intrinsic, direct hepatotoxin when administered in high doses (e.g., >1,800 mg/day or >100 mg/kg).35 Patients with autoimmune diseases such as systemic lupus erythematosus (SLE) or juvenile idiopathic arthritis who require high-dose therapy frequently exhibit moderate-to-marked elevations in serum ALT and AST.35 These enzyme elevations usually resolve within days of dose reduction or cessation.35 In patients with a history of liver problems, the threshold for this toxicity may be lower due to existing mitochondrial stress and impaired detoxification pathways.8 However, low-dose aspirin (81 mg) used for cardiovascular prevention is rarely associated with these dramatic enzyme shifts in the absence of severe failure.3

### Reye's Syndrome: The Pediatric Constraint

Reye's syndrome is a rare but potentially fatal condition characterized by acute non-inflammatory encephalopathy and microvesicular fat accumulation in the liver.35 It is almost exclusively triggered by the use of aspirin in children or teenagers during an acute febrile viral illness, such as influenza or varicella.35 The biochemical mechanism involves an aspirin-induced inhibition of mitochondrial beta-oxidation, leading to hyperammonemia and hepatic failure.35 Consequently, while low-dose aspirin might be considered in adults with liver history, it remains strictly contraindicated in the pediatric population during viral episodes, regardless of their liver health history.42

## Aspirin for Cardiovascular Prophylaxis in Liver Patients

The decision to initiate aspirin for cardiovascular prevention in liver patients must navigate the evolving—and increasingly conservative—guidelines from major heart societies.44

### Primary vs. Secondary Prevention

For secondary prevention (patients with established cardiovascular disease), the benefit of low-dose aspirin in reducing recurrent myocardial infarction or stroke is well-established, reducing vascular events by approximately 21%.46 In such cases, even in the presence of compensated liver disease, the anti-thrombotic benefit often outweighs the bleeding risk, though shared decision-making is essential.46

For primary prevention (patients without established CVD), the consensus has shifted. The 2022 USPSTF and 2019 ACC/AHA guidelines now recommend against routine aspirin use in adults over 60 years or those at increased risk of bleeding.45

| **Risk Category** | **Guideline Assessment** | **Implications for Liver History** |
| --- | --- | --- |
| **History of GI Bleeding** | Increased Bleeding Risk 47 | Primary prevention discouraged. |
| **Age > 70** | Increased Bleeding Risk 47 | Primary prevention contraindicated. |
| **Thrombocytopenia** | Increased Bleeding Risk 47 | Primary prevention discouraged. |
| **Chronic Kidney Disease** | Increased Bleeding Risk 47 | Primary prevention discouraged. |
| **Cirrhosis** | Increased Bleeding Risk 2 | Routine use for primary prevention generally not justified. |

In this context, most patients with a significant "history of liver problems"—particularly those with any degree of portal hypertension or renal impairment—would be classified in the "high bleeding risk" category, where the harms of aspirin for primary prevention are likely to exceed the benefits.47

## Clinical Monitoring and Risk Mitigation Strategies

In clinical scenarios where the benefits of low-dose aspirin are deemed essential (e.g., following coronary artery stenting in a patient with compensated liver disease), specific strategies can be employed to mitigate potential hazards.2

1. **Gastrointestinal Protection**: The concurrent use of a proton pump inhibitor (PPI) is strongly recommended to reduce the incidence of aspirin-induced gastric ulcers and subsequent bleeding.2
2. **Renal Surveillance**: Regular monitoring of serum creatinine, electrolytes, and urine output is necessary to detect early signs of drug-induced AKI.2
3. **Variceal Screening**: Before initiating long-term aspirin in a cirrhotic patient, endoscopic screening for esophageal varices is prudent.2 If large varices are present, prophylactic banding or non-selective beta-blockers (NSBBs) should be optimized.34
4. **Platelet Monitoring**: Maintenance of a platelet count above 50,000/µL is generally considered a safety buffer for antiplatelet therapy.36 If the count falls below this threshold, the risk of major bleeding increases exponentially.36

### Platelet Thresholds for Invasive Procedures and Maintenance

| **Platelet Count (cells/µL)** | **Risk Classification** | **Clinical Recommendation** |
| --- | --- | --- |
| **> 150,000** | Normal | No specific liver-related antiplatelet restriction. |
| **100,000 – 150,000** | Mild Thrombocytopenia | Generally safe; standard monitoring.52 |
| **50,000 – 100,000** | Moderate Thrombocytopenia | Safe for maintenance; caution with dual antiplatelet therapy.36 |
| **10,000 – 50,000** | Severe Thrombocytopenia | High risk; single-agent aspirin only if life-threatening.36 |
| **< 10,000** | Extremely Severe | Aspirin essentially contraindicated; risk of spontaneous bleed.36 |

## Comparative Safety: Aspirin vs. Clopidogrel in Liver Disease

Emerging data, such as the HOST-EXAM Extended study, suggest that clopidogrel may be a safer and more effective alternative for long-term maintenance after coronary intervention, particularly in high-bleeding-risk (HBR) populations.11 Clopidogrel monotherapy was associated with a 29% reduction in the composite endpoint of death, MI, or stroke compared to aspirin, without increasing major bleeding.11

From a hepatological perspective, clopidogrel offers a distinct safety advantage: it does not possess the prostaglandin-inhibiting properties of aspirin.10 In pharmacokinetic studies of cirrhotic patients (Child-Pugh A and B), clopidogrel’s inhibition of platelet aggregation was comparable to healthy controls, and no dose adjustment was required based on liver function.10 For liver patients requiring cardiovascular protection, clopidogrel may represent a more stable pharmacological choice, avoiding the renal complications that frequently complicate aspirin use in this population.10

## Synthesis and Conclusion

The scientific evidence suggests that the "safety" of low-dose aspirin in patients with a history of liver problems is entirely dependent on the specific stage and etiology of the liver disease. In the context of MASLD and compensated viral hepatitis, the data lead toward a potential therapeutic benefit, characterized by reduced liver fat, decreased inflammation, and significant long-term chemoprevention of hepatocellular carcinoma. In these stable, pre-cirrhotic populations, low-dose aspirin (81–100 mg) is generally well-tolerated and associated with improved liver-specific outcomes.

However, the safety profile disintegrates upon the onset of decompensated cirrhosis. The pharmacological inhibition of renal prostaglandins by aspirin poses a direct threat to kidney function in patients who rely on these vasodilators to maintain renal blood flow. Furthermore, the combination of portal hypertension and aspirin-induced platelet dysfunction elevates the risk of life-threatening variceal hemorrhage.

The data therefore suggest a bifurcated approach. In early-stage liver disease, aspirin represents a promising tool for disease modification and cancer prevention. In advanced liver disease, particularly with ascites or a MELD score exceeding 15, the risks of renal failure and catastrophic bleeding make aspirin an unsafe option. For clinicians managing this population, the priority must be a meticulous assessment of renal function, portal pressure, and hemostatic reserve, ensuring that the drive for cardiovascular or oncological prevention does not inadvertently trigger a terminal hepatic decompensation.

#### Works cited

1. AASLD PRACTICE GUIDELINE Introduction to the ... - Rackcdn.com, accessed February 5, 2026, <https://6443bb74ef7c532515d0-3858179a21f8875f9590fc888a54448a.ssl.cf2.rackcdn.com/aasld_a24ed4040689b31e6004ba08b019acee.pdf>
2. Why should aspirin (acetylsalicylic acid) be avoided in patients with cirrhotic liver disease?, accessed February 5, 2026, <https://www.droracle.ai/articles/274510/why-should-aspirin-acetylsalicylic-acid-be-avoided-in-patients>
3. DAILY ASPIRIN THERAPY FOR THE TREATMENT OF METABOLIC ..., accessed February 5, 2026, <https://www.aasld.org/the-liver-meeting/daily-aspirin-therapy-treatment-metabolic-dysfunction-associated-steatotic-liver>
4. Five Years Of Regular Aspirin Use Helps Prevent Common Liver Cancer - AASLD, accessed February 5, 2026, <https://www.aasld.org/news/five-years-regular-aspirin-use-helps-prevent-common-liver-cancer>
5. Association of aspirin use alone with mortality and liver-related events in MASLD: a multi-institutional three-year study - NIH, accessed February 5, 2026, <https://pmc.ncbi.nlm.nih.gov/articles/PMC12536622/>
6. Aspirin and hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease: nationwide cohort study with genetic risk analysis - PMC - NIH, accessed February 5, 2026, <https://pmc.ncbi.nlm.nih.gov/articles/PMC12835774/>
7. Hepatorenal Syndrome - American Liver Foundation, accessed February 5, 2026, <https://liverfoundation.org/liver-diseases/complications-of-liver-disease/hepatorenal-syndrome/>
8. Pharmacokinetics of aspirin: evaluating shortcomings in the literature, accessed February 5, 2026, <https://www.tandfonline.com/doi/full/10.1080/17425255.2024.2386368>
9. Understanding Aspirin - A Pharmacokinetic Perspective - Latrina Walden Exam Solutions, accessed February 5, 2026, <https://shop.latrinawaldenexamsolutions.com/blogs/pmhnp/aspirin-pharmacokinetics>
10. Is clopidogrel (Plavix) safe to use in patients with cirrhosis (liver disease)? - Dr.Oracle, accessed February 5, 2026, <https://www.droracle.ai/articles/517097/is-clopidogrel-plavix-safe-to-use-in-patients-with>
11. Long-Term Aspirin vs Clopidogrel After Coronary Stenting by Bleeding Risk and Procedural Complexity - European Society of Cardiology, accessed February 5, 2026, <https://www.escardio.org/communities/working-groups/thrombosis/scientific-documents-and-publications/commented-articles/long-term-aspirin-vs-clopidogrel-after-coronary-stenting-by-bleeding-risk-and-procedural-complexity/>
12. Can a patient with liver cirrhosis take aspirin (acetylsalicylic acid) 325 milligrams daily?, accessed February 5, 2026, <https://www.droracle.ai/articles/32120/can-a-patient-with-liver-cirrhosis-take-aspirin-acetylsalicylic>
13. Evaluating the Role of Aspirin in Liver Disease: Efficacy, Safety, Potential Benefits and Risks, accessed February 5, 2026, <https://pmc.ncbi.nlm.nih.gov/articles/PMC11679757/>
14. Aspirin cuts liver fat in trial - Harvard Gazette, accessed February 5, 2026, <https://news.harvard.edu/gazette/story/2024/03/aspirin-cuts-liver-fat-in-trial/>
15. Associations between use of aspirin and MRI-derived liver fat and fibroinflammation, accessed February 5, 2026, <https://www.medrxiv.org/content/10.64898/2025.12.23.25342902v1.full>
16. Aspirin on the prevention of hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease - ResearchGate, accessed February 5, 2026, <https://www.researchgate.net/publication/400223095_Aspirin_on_the_prevention_of_hepatocellular_carcinoma_in_metabolic_dysfunction-associated_steatotic_liver_disease>
17. Utility of aspirin in the treatment of fatty liver - Clínica FEHV, accessed February 5, 2026, <https://fehv.org/en/utility-of-aspirin-in-the-treatment-of-fatty-liver/>
18. Full article: Association of aspirin use alone with mortality and liver-related events in MASLD: a multi-institutional three-year study - Taylor & Francis, accessed February 5, 2026, <https://www.tandfonline.com/doi/full/10.1080/07853890.2025.2573146>
19. Daily aspirin associated with a reduced risk of hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: a population-based cohort study - NIH, accessed February 5, 2026, <https://pmc.ncbi.nlm.nih.gov/articles/PMC10331813/>
20. Aspirin Use and Risk of HCC and Gastrointestinal Bleeding in Patients With HBV-Related Cirrhosis: A Landmark Analysis - PubMed, accessed February 5, 2026, <https://pubmed.ncbi.nlm.nih.gov/41030108/>
21. Association of Daily Aspirin Therapy With Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B - PMC - NIH, accessed February 5, 2026, <https://pmc.ncbi.nlm.nih.gov/articles/PMC6503573/>
22. Low-dose aspirin linked to reduced liver cancer risk in chronic hepatitis B and hepatitis C patients - British Liver Trust, accessed February 5, 2026, <https://britishlivertrust.org.uk/low-dose-aspirin-linked-to-reduced-liver-cancer-risk-in-chronic-hepatitis-b-and-hepatitis-c-patients/>
23. Low-Dose Aspirin May Lower Risk of Hepatocellular Carcinoma & Liver-Related Mortality, accessed February 5, 2026, <https://www.cancernetwork.com/view/low-dose-aspirin-may-lower-risk-hepatocellular-carcinoma-liver-related-mortality>
24. Daily Aspirin Reduced the Incidence of Hepatocellular Carcinoma ..., accessed February 5, 2026, <https://pmc.ncbi.nlm.nih.gov/articles/PMC10251874/>
25. Influence of Aspirin on Hospital and Clinical Outcomes in Hepatocellular Carcinoma: Insights from National Data - MDPI, accessed February 5, 2026, <https://www.mdpi.com/2036-7422/16/3/33>
26. Evidence Grows | Harvard Medical School, accessed February 5, 2026, <https://hms.harvard.edu/news/evidence-grows>
27. Daily aspirin use associated with reduced risk for fibrosis progression in patients with nonalcoholic fatty liver disease - PMC, accessed February 5, 2026, <https://pmc.ncbi.nlm.nih.gov/articles/PMC6842070/>
28. (PDF) Aspirin Use and Risk of HCC and Gastrointestinal Bleeding in Patients With HBV-Related Cirrhosis: A Landmark Analysis - ResearchGate, accessed February 5, 2026, <https://www.researchgate.net/publication/396054962_Aspirin_Use_and_Risk_of_HCC_and_Gastrointestinal_Bleeding_in_Patients_With_HBV-Related_Cirrhosis_A_Landmark_Analysis>
29. Aspirin Use and Risk of HCC and Gastrointestinal Bleeding in Patients With HBV‐Related Cirrhosis: A Landmark Analysis - PMC - NIH, accessed February 5, 2026, <https://pmc.ncbi.nlm.nih.gov/articles/PMC12581848/>
30. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis, accessed February 5, 2026, <https://easl.eu/wp-content/uploads/2018/10/decompensated-cirrhosis-English-report.pdf>
31. Acute renal dysfunction in liver diseases - PMC - NIH, accessed February 5, 2026, <https://pmc.ncbi.nlm.nih.gov/articles/PMC4172733/>
32. Hepatorenal Syndrome - DynaMed, accessed February 5, 2026, <https://www.dynamed.com/condition/hepatorenal-syndrome>
33. Renal Dysfunction in Cirrhosis: Diagnosis, Treatment, and Prevention - PubMed Central, accessed February 5, 2026, <https://pmc.ncbi.nlm.nih.gov/articles/PMC1480573/>
34. Back to Basics: Outpatient Management of Cirrhosis - AASLD, accessed February 5, 2026, <https://www.aasld.org/liver-fellow-network/core-series/back-basics/back-basics-outpatient-management-cirrhosis>
35. Aspirin - LiverTox - NCBI Bookshelf - NIH, accessed February 5, 2026, <https://www.ncbi.nlm.nih.gov/books/NBK548900/>
36. At what level of thrombocytopenia is Aspirin (Acetylsalicylic Acid) contraindicated?, accessed February 5, 2026, <https://www.droracle.ai/articles/204198/at-what-level-of-thrombocytopenia-is-aspirin-acetylsalicylic-acid>
37. New EASL CPGs provide guidance on preventing and managing ..., accessed February 5, 2026, <https://easl.eu/news/cpgs-2022/>
38. MELD Score: Calculating & Interpreting Results - Cleveland Clinic, accessed February 5, 2026, <https://my.clevelandclinic.org/health/diagnostics/meld-score>
39. Review article: the safety of anticoagulants and antiplatelet agents in patients with cirrhosis, accessed February 5, 2026, <https://www.researchgate.net/publication/365362050_Review_article_the_safety_of_anticoagulants_and_antiplatelet_agents_in_patients_with_cirrhosis>
40. MELD Score - Viral Hepatitis and Liver Disease, accessed February 5, 2026, <https://www.hepatitis.va.gov/cirrhosis/background/cirrhosis-meld-score.asp>
41. Aspirin (Bayer, Vazalore, and others) - Uses, Side Effects, and More - WebMD, accessed February 5, 2026, <https://www.webmd.com/drugs/aspirin>
42. Aspirin Uses, Dosage, Side Effects & Interactions - Drugs.com, accessed February 5, 2026, <https://www.drugs.com/aspirin.html>
43. ASPIRIN tablet - DailyMed, accessed February 5, 2026, <https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d8b5d5b4-44d2-4f8f-8c11-e4fc96504f59>
44. ACC/AHA Guidelines Discourage Aspirin Use for Primary ASCVD Prevention, accessed February 5, 2026, <https://www.consultant360.com/consultant360/primary-care/accaha-guidelines-discourage-aspirin-use-primary-ascvd-prevention>
45. Aspirin for primary prevention of cardiovascular disease: What do the current USPSTF guidelines say? | Cleveland Clinic Journal of Medicine, accessed February 5, 2026, <https://www.ccjm.org/content/90/5/287>
46. Aspirin for the Primary Prevention of Cardiovascular Disease: Time for a Platelet-Guided Approach | Arteriosclerosis, Thrombosis, and Vascular Biology, accessed February 5, 2026, <https://www.ahajournals.org/doi/10.1161/ATVBAHA.122.318020>
47. ACC / AHA Guideline Recommendations: Low Dose Aspirin for Primary CVD Prevention, accessed February 5, 2026, <https://pcmedproject.com/cardiology/acc-aha-guideline-recommendations-low-dose-aspirin-for-primary-cvd-prevention/>
48. Recommendation: Aspirin Use to Prevent Cardiovascular Disease: Preventive Medication | United States Preventive Services Taskforce - uspstf, accessed February 5, 2026, <https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/aspirin-to-prevent-cardiovascular-disease-preventive-medication>
49. Guideline concordance of aspirin use for primary prevention in adult outpatients, accessed February 5, 2026, <https://ashpublications.org/bloodadvances/article/8/24/6207/518101/Guideline-concordance-of-aspirin-use-for-primary>
50. Aspirin for Primary Prevention of Cardiovascular Disease - Medi-Cal Rx, accessed February 5, 2026, <https://medi-calrx.dhcs.ca.gov/cms/medicalrx/static-assets/documents/provider/dur/educational-articles/dured_Aspirin_for_Primary_Prevention_of_Cardiovascular_Disease.pdf>
51. Aspirin for Primary Prevention of Cardiovascular Disease - PMC, accessed February 5, 2026, <https://pmc.ncbi.nlm.nih.gov/articles/PMC7379119/>
52. The management of antiplatelet therapy in acute coronary syndrome patients with thrombocytopenia: a clinical conundrum - PMC, accessed February 5, 2026, <https://pmc.ncbi.nlm.nih.gov/articles/PMC5837661/>
53. Minimum platelet count threshold before invasive procedures in cirrhosis: Evolution of the guidelines - PMC, accessed February 5, 2026, <https://pmc.ncbi.nlm.nih.gov/articles/PMC9988645/>
54. Clopidogrel Outperforms Aspirin Monotherapy Following PCI - American College of Cardiology, accessed February 5, 2026, <https://www.acc.org/About-ACC/Press-Releases/2025/03/30/15/43/Clopidogrel-Outperforms-Aspirin-Monotherapy>